

## **Akzo Nobel appoints Dr. Jörg Spiekerkötter as CFO of Organon BioSciences N.V.**

**Arnhem, the Netherlands, October 26, 2006 — Akzo Nobel has appointed Dr. Jörg Spiekerkötter as Chief Financial Officer of its subsidiary Organon BioSciences N.V. He will officially take up the position on November 1, 2006. He will also be nominated for appointment as a member of the Board of Management of Organon BioSciences N.V.**

Mr. Spiekerkötter (48) will join Organon BioSciences from Schering AG, where he was a member of the Executive Board responsible for Finance, Administration and Human Resources. His appointment marks an important landmark in the establishment of Akzo Nobel's Pharma businesses as a separate company.

Commenting on the appointment, Akzo Nobel CEO Hans Wijers said: "We are very pleased to have appointed Jörg Spiekerkötter as CFO of Organon BioSciences. He has been working in the biopharma industry since 1991 and his specific expertise in finance, law and human resources complements the profile of CEO Toon Wilderbeek. Together they will form a strong team to lead Organon BioSciences into the next phase of its development."

Mr. Spiekerkötter added: "I am looking forward to helping Organon BioSciences realize its ambitions as an independent company. I see Organon BioSciences as a highly professional business, driven by a clear ambition to deliver value from its excellent products and a healthy financial performance."

A German citizen, Mr. Spiekerkötter has held a number of senior positions within the biopharma industry. He was head of Finance at Schering AG and was appointed head of Legal, Trademarks and Insurances at Hoechst Schering Agrevo GmbH. A graduate of the Universities of Bielefeld, Lausanne and Freiburg, Mr. Spiekerkötter holds a doctorate degree in Law.

- - -

### **Note for the editor**

Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ more than 62,000 people and conduct our activities in four segments – human and animal health, coatings and chemicals – subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the full year will be published on February 15, 2007.

Internet: [www.akzonobel.com](http://www.akzonobel.com)

### **Not for publication – for more information**

Akzo Nobel nv  
Corporate Media Relations, tel. +31 26 366 43 43  
Contact: Tim van der Zanden

Akzo Nobel nv  
Velperweg 76  
P.O. Box 9300  
6800 SB Arnhem  
The Netherlands  
Tel +31 26 366 43 43  
Fax +31 26 366 49 40

**Safe Harbor Statement\***

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website [www.akzonobel.com](http://www.akzonobel.com).

\* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.